查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球肺部疾病治疗市场（疾病类型：哮喘、慢性阻塞性肺病、肺癌、其他肺部疾病）-全球行业分析、规模、份额、增长、趋势和预测，2022-2031 年
市场调查报告书
商品编码
1229628

全球肺部疾病治疗市场（疾病类型：哮喘、慢性阻塞性肺病、肺癌、其他肺部疾病）-全球行业分析、规模、份额、增长、趋势和预测，2022-2031 年

Lung Disease Therapeutics Market (Disease Type: Asthma, Chronic Obstructive Pulmonary Disease, Lung Cancer, and Other Lung Diseases) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 205 Pages | 商品交期: 2-10个工作天内

价格

本报告介绍了 2017 年至 2031 年全球肺部疾病治疗市场的收入，以 2022 年为基准年，2031 年为预测年。 它还展示了 2022 年至 2031 年全球肺部疾病治疗市场的复合年增长率 (CAGR %)。

这份报告是广泛研究的结果。 在初步研究中，分析师对主要思想领袖、行业领袖和舆论製造者进行了访谈，开展了大量研究工作。 在二次调研中，参考了各大公司的产品文献、年报、新闻稿、相关文件等，瞭解肺病治疗市场。

该报告深入探讨了全球肺部疾病治疗市场的竞争格局。 已经确定了在全球肺部疾病治疗市场运营的主要参与者，并对每家公司进行了不同属性的分析。 公司概况、财务状况、近期发展和 SWOT 是本报告中介绍的全球肺病治疗市场参与者的属性。

内容

第一章前言

  • 市场定义和范围
  • 市场细分
  • 主要研究目标
  • 调查要点

第 2 章假设和研究方法

第 3 章执行摘要：全球肺部疾病治疗市场

第 4 章市场概述

  • 介绍
    • 段定义
    • 行业的演变和发展
  • 概览
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • 2017-2031 年全球肺部疾病治疗市场分析与预测

第 5 章关键见解

  • 技术进步
  • 製药管道分析
  • 疾病流行率和发病率（按世界主要国家分类）
  • 区域/全球监管情景
  • COVID-19 影响分析

第6章全球肺部疾病治疗市场分析及预测

  • 介绍和定义
  • 重大发现/发展
  • 2017-2031 年按疾病类型划分的市场价值预测
    • 支气管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 按疾病类型进行市场吸引力分析

第 7 章肺部疾病治疗的全球市场分析和预测：按药物类别分类

  • 介绍和定义
  • 重大发现/发展
  • 2017-2031 年各药物类别的市场价值预测
    • 皮质类固醇
    • 支气管扩张药
    • 穆科里奇
    • 抗菌药
    • 其他
  • 市场吸引力分析：按药物类别

第 8 章全球肺部疾病治疗市场分析及预测（按分销渠道）

  • 介绍和定义
  • 重大发现/发展
  • 2017-2031 年各分销渠道的市场价值预测
    • 医院药房
    • 零售药房
    • 在线药店
  • 市场吸引力分析：按分销渠道

第 9 章肺部疾病治疗的全球市场分析和预测：按地区

  • 主要发现
  • 2017-2031 年各地区的市场价值预测
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第10章北美肺部疾病治疗市场分析及预测

  • 介绍
    • 主要发现
  • 2017-2031 年按疾病类型划分的市场价值预测
    • 支气管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各药物类别的市场价值预测
    • 皮质类固醇
    • 支气管扩张药
    • 穆科里奇
    • 抗菌药
    • 其他
  • 2017-2031 年各分销渠道的市场价值预测
    • 医院药房
    • 零售药房
    • 在线药店
  • 2017-2031 年各个国家/地区的市场价值预测
    • 美国
    • 加拿大
  • 市场吸引力分析
    • 按疾病类型
    • 按治疗类别
    • 按分销渠道
    • 按国家

第 11 章欧洲肺部疾病治疗市场分析和预测

  • 介绍
    • 主要发现
  • 2017-2031 年按疾病类型划分的市场价值预测
    • 支气管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各药物类别的市场价值预测
    • 皮质类固醇
    • 支气管扩张药
    • 穆科里奇
    • 抗菌药物
    • 其他
  • 2017-2031 年各分销渠道的市场价值预测
    • 医院药房
    • 零售药房
    • 在线药店
  • 2017-2031 年按国家/地区划分的市场价值预测
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 市场吸引力分析
    • 按疾病类型
    • 按治疗类别
    • 按分销渠道
    • 按国家/地区

第十二章亚太地区肺部疾病治疗市场分析及预测

  • 介绍
    • 主要发现
  • 2017-2031 年按疾病类型划分的市场价值预测
    • 支气管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各药物类别的市场价值预测
    • 皮质类固醇
    • 支气管扩张剂
    • 穆科里奇
    • 抗菌药
    • 其他
  • 2017-2031 年各分销渠道的市场价值预测
    • 医院药房
    • 零售药房
    • 在线药店
  • 2017-2031 年按国家/地区划分的市场价值预测
    • 中国
    • 日本
    • 印度
    • 澳大利亚和新西兰
    • 其他亚太地区
  • 市场吸引力分析
    • 按疾病类型
    • 按治疗类别
    • 按分销渠道
    • 按国家/地区

第 13 章拉丁美洲肺部疾病治疗市场分析和预测

  • 介绍
    • 主要发现
  • 2017-2031 年按疾病类型划分的市场价值预测
    • 支气管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各药物类别的市场价值预测
    • 皮质类固醇
    • 支气管扩张药
    • 穆科里奇
    • 抗菌药
    • 其他
  • 2017-2031 年各分销渠道的市场价值预测
    • 医院药房
    • 零售药房
    • 在线药店
  • 2017-2031 年按国家/地区划分的市场价值预测
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 市场吸引力分析
    • 按疾病类型
    • 按治疗类别
    • 按分销渠道
    • 按国家/地区

第14章中东和非洲肺部疾病治疗市场分析及预测

  • 介绍
    • 主要发现
  • 2017-2031 年按疾病类型划分的市场价值预测
    • 支气管哮喘
    • 慢性阻塞性肺疾病 (COPD)
    • 肺癌
    • 其他
  • 2017-2031 年各药物类别的市场价值预测
    • 皮质类固醇
    • 支气管扩张药
    • 穆科里奇
    • 抗菌药物
    • 其他
  • 2017-2031 年各分销渠道的市场价值预测
    • 医院药房
    • 零售药房
    • 在线药店
  • 2017-2031 年按国家/地区划分的市场价值预测
    • 海湾合作委员会国家
    • 南非
    • 其余中东和非洲地区
  • 市场吸引力分析
    • 按疾病类型
    • 按治疗类别
    • 按分销渠道
    • 按国家/地区

第15章竞争格局

  • 市场参与者 - 竞争矩阵（按公司层级和公司规模）
  • 市场份额分析：按公司分类（2021 年）
  • 公司简介
    • GSK
    • AstraZeneca
    • Boehringer Ingelheim
    • Novartis
    • Vertex Pharmaceuticals
    • F. Hoffman La Roche
    • Teva Pharmaceuticals
    • Cipla
    • Liminal Biosciences
    • Fibrogen
    • PharmAkea Therapeutics
    • IQVIA
Product Code: TMRGL85362

The report provides revenue of the global lung disease therapeutics market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung disease therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lung disease therapeutics market.

The report delves into the competitive landscape of the global lung disease therapeutics market. Key players operating in the global lung disease therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global lung disease therapeutics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Lung Disease Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Lung Disease Therapeutics Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Drug Pipeline Analysis
  • 5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.4. Regulatory Scenario by Region/Globally
  • 5.5. COVID-19 Impact Analysis

6. Global Lung Disease Therapeutics Market Analysis and Forecast, by Disease Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Disease Type, 2017-2031
    • 6.3.1. Asthma
    • 6.3.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 6.3.3. Lung Cancer
    • 6.3.4. Others
  • 6.4. Market Attractiveness Analysis, by Disease Type

7. Global Lung Disease Therapeutics Market Analysis and Forecast, by Drug Class

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Drug Class, 2017-2031
    • 7.3.1. Corticosteroids
    • 7.3.2. Bronchodilator Medications
    • 7.3.3. Mucolytics
    • 7.3.4. Antimicrobial Medications
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Drug Class

8. Global Lung Disease Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Lung Disease Therapeutics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Lung Disease Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Disease Type, 2017-2031
    • 10.2.1. Asthma
    • 10.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 10.2.3. Lung Cancer
    • 10.2.4. Others
  • 10.3. Market Value Forecast, by Drug Class, 2017-2031
    • 10.3.1. Corticosteroids
    • 10.3.2. Bronchodilator Medications
    • 10.3.3. Mucolytics
    • 10.3.4. Antimicrobial Medications
    • 10.3.5. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Disease Type
    • 10.6.2. By Drug Class
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Lung Disease Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Disease Type, 2017-2031
    • 11.2.1. Asthma
    • 11.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 11.2.3. Lung Cancer
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Drug Class, 2017-2031
    • 11.3.1. Corticosteroids
    • 11.3.2. Bronchodilator Medications
    • 11.3.3. Mucolytics
    • 11.3.4. Antimicrobial Medications
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Disease Type
    • 11.6.2. By Drug Class
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Lung Disease Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Disease Type, 2017-2031
    • 12.2.1. Asthma
    • 12.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 12.2.3. Lung Cancer
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Drug Class, 2017-2031
    • 12.3.1. Corticosteroids
    • 12.3.2. Bronchodilator Medications
    • 12.3.3. Mucolytics
    • 12.3.4. Antimicrobial Medications
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Disease Type
    • 12.6.2. By Drug Class
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Lung Disease Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Disease Type, 2017-2031
    • 13.2.1. Asthma
    • 13.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 13.2.3. Lung Cancer
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Drug Class, 2017-2031
    • 13.3.1. Corticosteroids
    • 13.3.2. Bronchodilator Medications
    • 13.3.3. Mucolytics
    • 13.3.4. Antimicrobial Medications
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Disease Type
    • 13.6.2. By Drug Class
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Lung Disease Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Disease Type, 2017-2031
    • 14.2.1. Asthma
    • 14.2.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 14.2.3. Lung Cancer
    • 14.2.4. Others
  • 14.3. Market Value Forecast, by Drug Class, 2017-2031
    • 14.3.1. Corticosteroids
    • 14.3.2. Bronchodilator Medications
    • 14.3.3. Mucolytics
    • 14.3.4. Antimicrobial Medications
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of MEA
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Disease Type
    • 14.6.2. By Drug Class
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2021)
  • 15.3. Company Profiles
    • 15.3.1. GSK
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Disease Type Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. AstraZeneca
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Disease Type Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Boehringer Ingelheim
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Disease Type Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Novartis
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Disease Type Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Vertex Pharmaceuticals
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Disease Type Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. F. Hoffman La Roche
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Disease Type Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Teva Pharmaceuticals
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Disease Type Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Cipla
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Disease Type Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Liminal Biosciences
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Disease Type Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Fibrogen
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Disease Type Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. PharmAkea Therapeutics
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Disease Type Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. IQVIA
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Disease Type Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 02: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 03: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 07: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 08: North America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 11: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12: Europe Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 15: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 16: Asia Pacific Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 19: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 20: Latin America Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 23: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 24: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Lung Disease Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
  • Figure 02: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Disease Type, 2021
  • Figure 03: Global Lung Disease Therapeutics Market Value Share, by Disease Type, 2021
  • Figure 04: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Drug Class, 2021
  • Figure 05: Global Lung Disease Therapeutics Market Value Share, by Drug Class, 2021
  • Figure 06: Global Lung Disease Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2021
  • Figure 07: Global Lung Disease Therapeutics Market Value Share, by Distribution Channel, 2021
  • Figure 08: Global Lung Disease Therapeutics Market Value Share, by Region, 2021
  • Figure 09: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: Global Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 11: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 12: Global Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 13: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 14: Global Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 15: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 16: Global Lung Disease Therapeutics Market Value Share Analysis, by Region, 2017 and 2031
  • Figure 17: Global Lung Disease Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 20: North America Lung Disease Therapeutics Market Value Share Analysis, by Country, 2017 and 2031
  • Figure 21: North America Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 22: North America Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 23: North America Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 24: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 25: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 26: North America Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 27: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 29: Europe Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 30: Europe Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 31: Europe Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 32: Europe Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 33: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 34: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 35: Europe Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 36: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 38: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 39: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 40: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 41: Asia Pacific Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 42: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 43: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 44: Asia Pacific Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 45: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 47: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 48: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 49: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 50: Latin America Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 51: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 52: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 53: Latin America Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 54: Middle East & Africa Lung Disease Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 56: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 57: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Disease Type, 2017 and 2031
  • Figure 58: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2031
  • Figure 59: Middle East & Africa Lung Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 60: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Disease Type, 2022-2031
  • Figure 61: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 62: Middle East & Africa Lung Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031